Description de l'entreprise
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies.
Conseil d'administration & Conseil de surveillance
| PDG |
| Prof. Dr. Dolores J. Schendel |
| Conseil d'administration |
| Axel-Sven Malkomes |
| Conseil de surveillance |
| Dr. Gerd Zettlmeissl, Antoinette Hiebeler-Hasner, Dr. Anthony Man, Dr. Frank Mathias, Dr. Keith Manchester, Ronald Scott |
Données de l'entreprise
| Nom: |
Medigene AG |
| Adresse: |
Lochhamer Str. 11,D-82152 Planegg/Martinsried |
| Téléphone: |
+49-89-200033-0 |
| Fax: |
+49-89-200033-2920 |
| Courriel: |
medigene@medigene.com
|
| Internet: |
www.medigene.com |
| Industrie: |
Biotechnology |
| Secteur: |
Biotechnology |
| Sous-secteur: |
Biotechnology |
| Fin de l'exercice financier: |
31/12 |
| Flotte libre: |
85.50% |
| IPO date: |
30/06/2000 |
Relations avec les investisseurs
| Nom: |
Dr. Anna Niedl |
| Téléphone IR: |
+49-89-200033-3301 |
| IR-Fax: |
- |
| E-mail IR: |
investor@medigene.com
|
